Alexia Cortella
Psychiatry · Newtown, CTNPI 1063996221
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,165 of the $120,245 with a category attached, or 63.3%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 94.3% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $74,061, more than ten times the $547 reported in 2021. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 547 payments — averaging $219.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$113K
- Corium, LLC$3K
- AbbVie$2K
- Collegium Pharmaceutical, Inc.$282
- Otsuka America Pharmaceutical, Inc.$257
- E.r. Squibb & Sons, L.L.C.$248
- plus $1K from 17 others
What the payments were for
- Consulting fees$3,5703%
- Speaking & faculty fees$76,16563%
- Travel & lodging$29,11124%
- Food & beverage$11,4009%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 214 | $113,426 |
| Corium, LLC | 85 | $2,855 |
| AbbVie | 138 | $1,833 |
| Collegium Pharmaceutical, Inc. | 20 | $282 |
| Otsuka America Pharmaceutical, Inc. | 9 | $257 |
| E.r. Squibb & Sons, L.L.C. | 11 | $248 |
| Alkermes, Inc. | 12 | $227 |
| Supernus Pharmaceuticals, Inc. | 13 | $197 |
| Neurocrine Biosciences, Inc. | 7 | $142 |
| Almatica Pharma LLC | 6 | $133 |
| Axsome Therapeutics, Inc. | 5 | $105 |
| Lundbeck LLC | 4 | $92 |
| Tris Pharma Inc | 5 | $92 |
| Ironshore Pharmaceuticals Inc. | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Tempus AI, Inc | 2 | $39 |
| TMS Neurohealth Centers Inc. | 1 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Neuronetics, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$120,245 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 23 | $69,523 |
| CaplytaLumateperone Tosylate | 16 | $34,696 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,451 |
| Quetiapine Fumarate | 52 | $1,395 |
| Lamotrigine | 59 | $1,254 |
| Duloxetine Hcl | 30 | $1,027 |
| Buspirone Hcl | 34 | $638 |
| Aripiprazole | 33 | $582 |
| Mirtazapine | 28 | $523 |
| Trazodone Hcl | 71 | $477 |
| Ziprasidone Hcl | 12 | $456 |
| Hydroxyzine Pamoate | 29 | $414 |
| Clonazepam | 38 | $395 |
| Gabapentin | 16 | $384 |
| Sertraline Hcl | 38 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $257 | $69,52323 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $113,426 | $34,69616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $62 | $13,45118 claims |
| Almatica Pharma LLCSertraline Hcl | $133 | $26338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Newtown
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.